USA flag logo/image

An Official Website of the United States Government

Enhanced Ozone Disinfection of Biofilms in Waterlines

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
66308
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
DE012560
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Compact Membrane Systems, Inc.
335 Water Street Newport, DE 19804-2410
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2003
Title: Enhanced Ozone Disinfection of Biofilms in Waterlines
Agency: HHS
Contract: 2R44DE012560-02A2
Award Amount: $839,213.00
 

Abstract:

DESCRIPTION (provided by applicant): Dental Unit Waterlines have come under increasing scrutiny as residents of biofilms which harbor and release bacteria and in some instances harmful pathogens. As a result ADA has pro actively recommended that the water delivered by dental equipment have <200 colony forming units (CFU) of heterotrophic, mesophilic bacteria/ml of water. To date we have significantly exceeded our Phase 1 objectives. We demonstrated that within 5 minutes, moderate levels of dissolved O3 (>3 mg per liter) can remove all of the planktonic bacteria and reduce biofilm levels by 99.99%. This suggerts that routine treatment (e.g. 1 hour/day) with O3 will treat both free floating planktonic bacteria and biofilms. We have also shown through the use of a confocal laser scanning microscope that >50% of the microbial load in the biofilm can be inactivated within three minutes of treatment. We also demonstrated the supply of dissolved O3 in water without bubbles using composite CMS perfluoromembranes on chemically resistant micro porous supports. In parallel we have also established a commercial supply of CMS membrane devices for bubbleless O3 delivery and have demonstrated the performance of a commercial chemically inert CMS membrane device for ozone dissolution. Since we have the key components in place, commercialization of the O3 delivery system is simplified. Phase II will focus on expanding this technology towards the delivery of a functional prototype for clinical testing at a dental practice. We have brought on board 2 biofilm experts to evaluate biofilm removal and study potential for regrowth. Customization of the membrane device will be conducted during the Phase II study, prior to market introduction during Phase III.

Principal Investigator:

Stuart Nemser
3029997955
snemser@compactmembrane.com

Business Contact:

Stuart Nemser
3029997996
SNEMSER@COMPACTMEMBRANE.COM
Small Business Information at Submission:

COMPACT MEMBRANE SYSTEMS, INC.
325 WATER STREET WILMINGTON, DE 18904

EIN/Tax ID: 510348256
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No